Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a pilot study twelve patients with malignant disease were treated with Corynebacterium parvum. The clinical results were encouraging. A prospective randomised controlled clinical trial of C. parvum therapy in the treatment of patients with carcinoma of the bronchus began in August 1976. 22 pateints have been admitted to the trial and 11 treated with C. parvum. Clinical progress is reported. Radiological, haematological, biochemical and immunological measurements have been made and these results are presented with emphasis on the immunological data. Marked elevation of C. parvum antibody titre occurs. Lymphocyte reactivity, assessed by responses to phytohaemagglutinin and poke-weed mitogen and by the formation of T and B-cell rosettes, was significantly depressed in all patients compared to healthy volunteers, but in patients receiving C. parvum there is a relative increase in B-lymphocyte activity. Mild platelet depression occurs. No alteration to complement activity has been detected.
 ...
PMID:Clinical studies with Corynebacterium parvum. 34 5

In 52 patients undergoing tests of cell-mediated immunity before surgical resection of bronchial carcinoma a positive tuberculin test result was found in 71% compared with 68% of age- and sex-matched controls. Sensitisation to DNCB occurred in 52% of 37 patients but in 78% of controls. There was depression of lymphocyte transformation by PPD in 19 patients compared with controls (P=0.001), but there was no difference in lymphocyte transformation by PHA or pokeweed mitogen between 34 patients and controls. In a pilot study patients were randomly allocated to autograft (eight) or non-autograft (seven) groups. The autograft group were given an intradermal injection of a suspension of irradiated autologous tumour-cells mixed with intradermal BCG on the day of operation. Tests of cell-mediated immunity were repeated two weeks after operation. Five patients in each group received a course of radiotherapy to the mediastinum three weeks after operation. There was a rise in cutaneous tuberculin reactivity (P=0.08) and total leucocyte count (P=0.09) in the autograft group postoperatively with a fall in total lymphocyte and T lymphocyte counts in the non-autograft group (P less 0.05). These differences, however, were not followed by any difference in the frequency of tumour recurrence or the survival rate two years after operation. The results show that the immunological surveillance mechanism is impaired even in patients with early bronchial carcinoma and that it is possible to overcome postoperative immunological depression with specific immunotherapy combined with BCG. This treatment did not produce any clinical advantage in this small number of patients and the skin lesions caused the patients considerable discomfort.
 ...
PMID:Cell-mediated immunity in operable bronchial carcinoma: the effect of injecting irradiated autologous tumour cells and BCG. 44 2

The authors studied the immunitary responses to Levamisole in a group of patients recently operated for bronchogenic carcinoma. The results were compared with those obtained from two other groups, i.e. one of patients recently operated of bronchogenic carcinoma but not treated with Levamisole and another one of patients recently operated for a non-neoplastic disease and also not treated with Levamisole. All subjects underwent a similar investigation of the cell-mediated and the humoral immunity parameters at the beginning of the study and after 30 days. The comparison of the results showed a depression of the cell-mediated immunity in the patients operated for bronchogenic carcinoma. This depression subsided more promptly in patients submitted to Levamisole therapy. This effect was achieved particularly through a better blastogenic responsiveness to the PHA and an enhanced Rosettes E forming. The use of Levamisole in the pre- and post-operative period is thought to be beneficial in order to avoid distant recurrences. This effect is obtained by a stimulation of host defense mechanisms.
 ...
PMID:[Levamisole-induced immunitary responses in patients operated from bronchogenic carcinoma (author's transl)]. 50 48

Serum immunoglobulin IgG, IgA and IgM levels were estimated in 112 patients with bronchogenic carcinoma, and the obtained values were as follows: IgG = 1762 +/- 595 mg/100 ml; IgA = 332 +/- 104 mg/100 ml; IgM = 157 +/- 76 mg/100 ml. Subsequently the patients were divided in a group of 74 patients with epidermoid carcinoma, and a group of 38 patients with small cell anaplastic carcinoma of the bronchus. In patients with epidermoid carcinoma, in cases with disseminated disease the mean survival was shorter (7.9 months) when compared to the mean survival of patients with localized disease (20.8 months). Similarly, a depression of lymphocyte counts was observed in cases with disseminated disease. In cases with IgA concentrations ranging from 300 to 410 mg/100 ml longer survival rates were observed. In patients with small cell anaplastic carcinoma variety, the survival rates in patients with localized disease were almost identical with those in patients with disseminated disease (11.4 months versus 9.9 months). The longest survival rates were observed in cases with IgG concentrations ranging from 1600 to 2100 mg/100 ml, and IgM concentrations ranging from 190 to 320 mg/100 ml of serum.
 ...
PMID:Serum immunoglobulin levels and survival rates in bronchogenic carcinoma patients. 54 9

Chemotaxis of blood monocytes was measured in 31 patients with bronchial carcinoma and 19 cigarette smokers. Thirteen patients with metastatic bronchial carcinoma had significantly less (P less than 0.005) chemotactic response than matched controls. Those with disease confined to the chest, or with recurrent or operable bronchial carcinoma, had no significant depression of monocyte chemotaxis. There was also no significant difference in monocyte chemotaxis between cigarette smokers and matched controls. These results support the concept that in human cancer there is a defect in monocyte chemotaxis, but in bronchial carcinoma significant depression was only apparent in those with advanced disease.
 ...
PMID:Monocyte chemotaxis in bronchial carcinoma and cigarette smokers. 58 13

Untreated patients with bronchogenic carcinoma of the epidermoid type showed a marked depression of cutaneous delayed hypersensitivity reactions to DNCB, PPD and Varidase. As compared to a control group of healthy individuals and to a control group of patients with non-malignant chest diseases, 46% of cases responded to the DNCB skin test, 56% to the PPD skin test and 39% to the Varidase skin test. The patients were subsequently divided according to the TNM classification in stage I, II and III groups. Correlation of the skin test positivity to the stage of the disease and to the survival of patients was followed.
 ...
PMID:Prognostic significance of skin reactivity in patients with bronchogenic carcinoma grouped according to the TNM classification. 59 68

Adriamycin was administered to 60 adults and 21 children by 3 different dosage schedules: 22.5 mg/sq m (0.6 mg/kg) daily for 4 days, 15 mg/sq m (0.4 mg/kg) every 8 hr for a total of 6 doses, and 50 to 120 mg/sq m as a single dose every 3 to 4 weeks. Objective responses lasting more than 1 month occurred in 5 subjects with acute leukemias or lymphoma, 3 with transitional cell carcinomas, 2 with sarcomas, 2 with Ewing's sarcoma and 1 each with bronchogenic carcinoma, orchidoblastoma, and thymoma. Toxic reactions included nausea, vomiting, stomatitis, alopecia, and hematopoietic depression, but significant cardiac toxicity occurred in only 1 patient. Pharmacokinetic data, collected in 25 patients by fluorometric and chromatographic assay, suggested a biphasic plasma clearance of drug with initial and secondary half-lives of about 1.5 and 14 to 21 hr, respectively. When drug was given every 8 hr there was evidence of loss of an initial very rapid phase of distribution of adriamycin and its metabolites. Urinary excretion accounted for 3.4 to 38.1% of administered fluorescence over a 72-hr period; in the first 24 hr, between 48.2 and 100% of this urinary material was in the form of adriamycin; leter, this fraction declined. No adriamycin or its fluorescent metabolites could be extracted from the stools.
 ...
PMID:Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. 94 83

Forty-seven patients with advanced small-cell bronchogenic carcinoma (SCLC) were treated with a combination of epirubicin (4-EPIDX) (60 mg/m2 i.v.) and cisplatin (CDDP) (50 mg/m2 i.v.) on day 1, alternated with cyclophosphamide (CTX) (800 mg/m2 i.v.) day 1 and etoposide (VP16) (120 mg/m2 i.v.) on days 21-23. Four patients (9%) obtained a complete remission and 27 (57%) a partial remission with an overall remission rate of 66%. The median duration of response was 37 weeks (range 13-150) and the median duration of survival was 43 weeks (range 10-150). No severe bone marrow depression was noted. The other side-effects were of a mild grade.
 ...
PMID:Small cell bronchogenic carcinoma: a cyclical alternating combination of epirubicin plus cisplatin and cyclophosphamide plus etoposide. 216 45

Twenty-seven patients with small cell bronchogenic carcinoma were treated with a combination of 4'-Epidoxorubicin 60 mg/m2 and cisplatin 50 mg/m2 i.v. every 3-4 weeks. Three patients (11%) had a complete remission (CR), and 12 (44%) had a partial remission (PR) with a 55% overall remission rate. The median duration of response was 36 weeks (range 11-256+). No severe bone marrow depression was noted. The other side effects were of mild grade. Because of the "minimal aggressiveness" of this combination for the patients, the results obtained in this preliminary phase can probably be improved by the integration of other drugs in the scheme.
 ...
PMID:4'-Epidoxorubicin plus cisplatin as first-line therapy in the treatment of small cell bronchogenic carcinoma. 303 79

472 computed tomographic (CT) examinations in 448 patients were reviewed for depression of the wall of the trachea and mainstem bronchi. Depression was defined as a neutral term, not indicating pressure exerted upon the wall. Such depressions appeared to occur very frequently as a variant. Special attention is paid to the so-called azygos vein indentation. The most marked depression variants in our series are reproduced. When a depression is found in contiguity with a pathological mass and does not exceed the range of the variants, one cannot be sure that the mass is indeed the cause of this depression. In patients with bronchogenic carcinoma, depression of the wall of the trachea or mainstem bronchus seems to be no better sign for the metastatic nature of lymphadenopathy than size per se.
 ...
PMID:Some anatomical variants and pitfalls in computed tomography of the trachea and mainstem bronchi. II. Compression or anatomical variants? 385 4


1 2 Next >>